Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors

NCT00088101 is registered in ClinicalTrials.gov with Synta Pharmaceuticals Corp. as lead sponsor.

NCT NCT00088101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00088101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors
Lead sponsor
Synta Pharmaceuticals Corp.
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2004
Completion date
December 31, 2004
Enrollment
42
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hematological malignancies, leukemia, lymphoma, metastatic or unresectable solid tumors